United Kingdom· GB-APID-45410011000001107
Tzield 2mg/2ml concentrate for solution for infusion vials
A teplizumab product containing teplizumab, registered in United Kingdom by Sanofi. The same ATC class is registered in 13 of our 19 countries.
Checked against NHS dm+d (United Kingdom) on
Informational only — not a medical device.
Where it is registered
Teplizumab is registered in 13 of 19 countries.
Countries holding a registration under ATC A10XX01 (teplizumab), each read from that country’s own register.
- This record: United Kingdom, from NHS dm+d (United Kingdom)
- 9 of them publish a price we can compare per daily dose
Teplizumab · ATC A10XX01
13 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
NHS dm+d (United Kingdom)- Active substance
- Teplizumab
- Manufacturer
- Sanofi
- Country
- United Kingdom (GB)
- ATC code
- A10XX01
- ATC class
- Teplizumab
- Reimbursed
- Not published by this register
- Source register
- NHS dm+d (United Kingdom)
- Last checked
- September 13, 2026
Packs & prices · 1
- gtin5000283663379
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Teplizumab in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesTZIELDProvention Bio, Inc.
- CzechiaTEIZEILDSanofi Winthrop Industrie, Gentilly
- SpainTEIZEILD 1 MG/ML CONCENTRADO PARA SOLUCION PARA PERFUSIONSanofi Winthrop Industrie
- FinlandTeizeildSanofi Winthrop Industrie
- FranceTEIZEILD 1 mg/1 mL, solution à diluer pour perfusionSANOFI WINTHROP INDUSTRIE
- BelgiumTeizeild 1 mg/mlSanofi Winthrop Industrie
- IcelandTeizeildSanofi Winthrop Industrie
- NetherlandsTeizeild 1 mg/ml concentraat voor oplossing voor infusieSanofi Winthrop Industrie
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Teizeild
- Liechtenstein · Teizeild
- Norway · Teizeild
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/43b1bcb5-16fd-4eea-8926-6dd6ef2c83c8 GET /v1/drugs/43b1bcb5-16fd-4eea-8926-6dd6ef2c83c8?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"apid": "45410011000001107",
"desc": "Tzield 2mg/2ml concentrate for solution for infusion vials (Sanofi)",
"form": "Solution for infusion",
"vpid": "45412811000001100",
"source": "dmd",
"vtm_id": "45410811000001101",
"strength": "1 mg",
"substance": "Teplizumab",
"ingredient": "Teplizumab",
"supplier_code": "9190711000001101"
}See everything about teplizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.